Back to top
more

Horizon Therapeutics Public Limited Company (HZNP)

(Real Time Quote from BATS)

$99.45 USD

99.45
463,861

-0.57 (-0.57%)

Updated Aug 2, 2021 12:49 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.57%
2Buy19.14%
3Hold10.74%
4Sell6.46%
5Strong Sell3.16%
S&P50011.27%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (214 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

Dublin, Ireland-based Horizon Therapeutics plc, previously known as Horizon Pharma plc, is a biopharmaceutical focused on making drugs in arthritis, pain, inflammatory and orphan diseases areas. Horizon Therapeutics (Horizon) was formed in September 2014, after Horizon, and Vidara acquired Ireland-based privately held specialty pharmaceutical company, Vidara Therapeutics International Ltd. through a reverse merger. On May 2, 2019, shareholders approved the change of the company’s name to Horizon Therapeutics. This move caters to the company’s long-term strategy to develop and commercialize innovative medicines addressing rare diseases, which currently have very few effective treatment options.

General Information

Horizon Therapeutics Public Limited Company

1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR

Dublin, L2 D04 C5Y6

Phone: 011-353-1772-2100

Fax: 224-383-3001

Web: http://www.horizontherapeutics.com

Email: investor-relations@horizontherapeutics.com

Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 6/30/2021
Next EPS Date 8/4/2021

EPS Information

Current Quarter EPS Consensus Estimate 0.91
Current Year EPS Consensus Estimate 3.62
Estimated Long-Term EPS Growth Rate 14.00
Next EPS Report Date 8/4/2021

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 100.02
52 Week High 104.86
52 Week Low 60.82
Beta 1.08
20 Day Moving Average 1,049,121.38
Target Price Consensus 116.30

HZNP

% Price Change
4 Week 4.33
12 Week 13.75
YTD 36.73
% Price Change Relative to S&P 500
4 Week 3.31
12 Week 9.54
YTD 16.85
Share Information
Shares Outstanding (millions) 224.77
Market Capitalization (millions) 22,481.35
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) 27.62
Trailing 12 Months 28.74
PEG Ratio 1.97
EPS Growth
vs. Previous Year -93.18%
vs. Previous Quarter -97.66%
   
Sales Growth
vs. Previous Year -3.79%
vs. Previous Quarter -54.06%
   
Price Ratios
Price/Book 5.83
Price/Cash Flow 19.20
Price / Sales 10.28
ROE
6/30/21 NA
3/31/21 22.28
12/31/20 27.73
ROA
6/30/21 NA
3/31/21 12.91
12/31/20 16.58
Current Ratio
6/30/21 NA
3/31/21 2.37
12/31/20 3.51
Quick Ratio
6/30/21 NA
3/31/21 2.06
12/31/20 3.42
Operating Margin
6/30/21 NA
3/31/21 35.75
12/31/20 38.98
Net Margin
6/30/21 NA
3/31/21 12.81
12/31/20 17.72
Pre-Tax Margin
6/30/21 NA
3/31/21 12.03
12/31/20 18.25
Book Value
6/30/21 NA
3/31/21 17.15
12/31/20 18.24
Inventory Turnover
6/30/21 NA
3/31/21 4.69
12/31/20 7.43
Debt-to-Equity
6/30/21 NA
3/31/21 0.66
12/31/20 0.25
Debt to Capital
6/30/21 NA
3/31/21 39.93
12/31/20 19.95